Knight Therapeutics signs a new distribution agreement with Gilead Sciences

▴ Knight Therapeutics signs a new distribution agreement with Gilead Sciences
The agreement will enter into force as of 1st January 2021

Knight Therapeutics Inc., a leading Pan American (ex. EU) specialty pharmaceutical company, announced the signing of a new exclusive distribution agreement with Gilead Sciences, Inc. for the marketing of AmBisome (liposomal amphotericin B) in Brazil. The agreement will enter into force as of 1st January 2021.

“We are pleased to continue this already established partnership and are very grateful to Gilead for the continued trust in the Knight team,” said Samira Sakhia, President and COO of Knight. Our Brazilian team launched AmBisome in Brazil over 20 years ago and we are excited to continue the great work we have done with patients and physicians ”.

"The signing of this new agreement extends the historic collaboration between Gilead and Grupo Biotoscana (" GBT ") and confirms Knight's assessment of the GBT acquisition," said Amal Khouri, vice president of business development at Knight.

“Gilead values ​​the ongoing partnership with GBT to meet medical needs in Brazil,” said Ahmed Afifi, vice president and head of the Latin America region at Gilead Sciences. With this new agreement, we are pleased to continue our cooperation with the extended GBT / Knight team to enable Brazilian patients to benefit from AmBisome ”.

AmBisome (Liposomal Amphotericin B) is a sterile lyophilized, non-pyrogenic intravenous infusion of liposomal amphotericin B. This medicinal product is indicated for the treatment of serious deep mycotic infections and / or endemic and opportunistic systemic mycoses, for the treatment of fever of undetermined origin (FOI) in neutropenic patients for whom the FOI corresponds persistent fever, which does not respond to antibiotic therapy after 96 hours and which is very indicative of a systemic fungal infection, as the primary therapy for visceral leishmaniasis in immunocompetent patients. AmBisome is a registered trademark of Gilead Sciences, Inc. and is the subject of a license from Gilead and has been in the portfolio of Knight's Brazilian subsidiary for over twenty years. Knight's subsidiaries are responsible for the distribution and commercial activities of AmBisome in Brazil as well as Bolivia, Paraguay and Peru.

Tags : #KnightTherapeutics #LatestNewsonKnightTherapeutics27thOct #GileadSciences #LatestNewsonGilead #Sciences27thOct #LatestPharmaNews27thOct #LatestPharmaCollaboration27thOct #BrainCancer #Brazil #AhmedAfifi #AmalKhouri

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

Covid technical Advisory panel advises Karnataka health dept to be prepared for 2nd wave of COVID-19 pandemicDecember 04, 2020
Telangana reports 631 fresh cases of COVID-19December 04, 2020
Odisha crosses milestone in conducting over 6 million tests for COVID-19December 04, 2020
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary EndpointDecember 04, 2020
Shape Therapeutics Unveils AAVid™ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene TherapyDecember 04, 2020
ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071 for the Treatment of Neonatal EncephalopathyDecember 04, 2020
I2O Therapeutics receives strategic investment from Colorcon VenturesDecember 04, 2020
Study shows personalized provider navigation using machine intelligence may reduce post-surgical hospitalizations and lower costsDecember 04, 2020
Zydus receives approval from DCGI to commence Phase III clinical trials with Pegylated Interferon alpha-2b in India December 04, 2020
PharmaEngine, Inc. collaborates with Sentinel Oncology for SOL-578, a Chk1 inhibitorDecember 04, 2020
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND ApplicationDecember 04, 2020
1450 new cases of COVID-19 reported in Madhya PradeshDecember 04, 2020
COVID-19 recovery rate in country improves to 94.20 pctDecember 04, 2020
Over 11,70,000 samples tested for COVID-19 across country in last 24 hoursDecember 04, 2020
Britain to cover COVID-19 vaccine side-effects under damages schemeDecember 04, 2020
India’s Active Caseload further dips to 4.35% of Total CasesDecember 04, 2020
COVID-19 recovery rate in Bihar improves to 97.12 pctDecember 04, 2020
Gujarat records 1540 new cases of COVID-19December 04, 2020
Catalyst Biosciences receives FDA Fast track designation for subcutaneous MarzAADecember 04, 2020
AbbVie and Frontier Medicines establish global partnership for research and developmentDecember 04, 2020